Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890188806> ?p ?o ?g. }
- W2890188806 endingPage "2297" @default.
- W2890188806 startingPage "2286" @default.
- W2890188806 abstract "Abstract β-thalassemias are genetic disorders characterized by anemia, ineffective erythropoiesis, and iron overload. Current treatment of severe cases is based on blood transfusion and iron chelation or allogeneic bone marrow (BM) transplantation. Novel approaches are explored for nontransfusion-dependent patients (thalassemia intermedia) who develop anemia and iron overload. Here, we investigated the erythropoietin (EPO) receptor partner, transferrin receptor 2 (TFR2), as a novel potential therapeutic target. We generated a murine model of thalassemia intermedia specifically lacking BM Tfr2: because their erythroid cells are more susceptible to EPO stimulation, mice show improved erythropoiesis and red blood cell morphology as well as partial correction of anemia and iron overload. The beneficial effects become attenuated over time, possibly due to insufficient iron availability to sustain the enhanced erythropoiesis. Germ line deletion of Tfr2, including haploinsufficiency, had a similar effect in the thalassemic model. Because targeting TFR2 enhances EPO-mediated effects exclusively in cells expressing both receptors, this approach may have advantages over erythropoiesis-stimulating agents in the treatment of other anemias." @default.
- W2890188806 created "2018-09-27" @default.
- W2890188806 creator A5005334724 @default.
- W2890188806 creator A5032248260 @default.
- W2890188806 creator A5050709615 @default.
- W2890188806 creator A5057071664 @default.
- W2890188806 creator A5060970793 @default.
- W2890188806 creator A5065413660 @default.
- W2890188806 creator A5075889001 @default.
- W2890188806 creator A5081960790 @default.
- W2890188806 creator A5082550914 @default.
- W2890188806 creator A5090031840 @default.
- W2890188806 date "2018-11-22" @default.
- W2890188806 modified "2023-10-13" @default.
- W2890188806 title "Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model" @default.
- W2890188806 cites W1484942319 @default.
- W2890188806 cites W1504583940 @default.
- W2890188806 cites W1547877665 @default.
- W2890188806 cites W1832707526 @default.
- W2890188806 cites W1844334486 @default.
- W2890188806 cites W1964891662 @default.
- W2890188806 cites W1974266372 @default.
- W2890188806 cites W1975590431 @default.
- W2890188806 cites W1978583741 @default.
- W2890188806 cites W1995509779 @default.
- W2890188806 cites W1999149952 @default.
- W2890188806 cites W2001248033 @default.
- W2890188806 cites W2004332359 @default.
- W2890188806 cites W2006046265 @default.
- W2890188806 cites W2010599622 @default.
- W2890188806 cites W2024591653 @default.
- W2890188806 cites W2025158365 @default.
- W2890188806 cites W2026199006 @default.
- W2890188806 cites W2033380296 @default.
- W2890188806 cites W2038317844 @default.
- W2890188806 cites W2038985536 @default.
- W2890188806 cites W2039975110 @default.
- W2890188806 cites W2049116122 @default.
- W2890188806 cites W2051875442 @default.
- W2890188806 cites W2064086288 @default.
- W2890188806 cites W2065862021 @default.
- W2890188806 cites W2071868364 @default.
- W2890188806 cites W2075795942 @default.
- W2890188806 cites W2076153728 @default.
- W2890188806 cites W2086667809 @default.
- W2890188806 cites W2088834051 @default.
- W2890188806 cites W2094190961 @default.
- W2890188806 cites W2101967659 @default.
- W2890188806 cites W2107089643 @default.
- W2890188806 cites W2111960139 @default.
- W2890188806 cites W2115311848 @default.
- W2890188806 cites W2128900735 @default.
- W2890188806 cites W2134650242 @default.
- W2890188806 cites W2142126764 @default.
- W2890188806 cites W2149986474 @default.
- W2890188806 cites W2151573971 @default.
- W2890188806 cites W2154504105 @default.
- W2890188806 cites W2155671850 @default.
- W2890188806 cites W2156150240 @default.
- W2890188806 cites W2163438420 @default.
- W2890188806 cites W2164322506 @default.
- W2890188806 cites W2179438025 @default.
- W2890188806 cites W2239159058 @default.
- W2890188806 cites W2286367365 @default.
- W2890188806 cites W2358356329 @default.
- W2890188806 cites W2401643476 @default.
- W2890188806 cites W2418024629 @default.
- W2890188806 cites W2508075031 @default.
- W2890188806 cites W2585591789 @default.
- W2890188806 cites W2618710293 @default.
- W2890188806 cites W2724525710 @default.
- W2890188806 cites W2739343830 @default.
- W2890188806 cites W2751938701 @default.
- W2890188806 cites W2766885087 @default.
- W2890188806 cites W2767181888 @default.
- W2890188806 cites W2768090721 @default.
- W2890188806 cites W2770567999 @default.
- W2890188806 cites W2776417147 @default.
- W2890188806 cites W2778083582 @default.
- W2890188806 cites W2781561019 @default.
- W2890188806 cites W2783530719 @default.
- W2890188806 cites W2793944650 @default.
- W2890188806 cites W2802087233 @default.
- W2890188806 cites W4211214940 @default.
- W2890188806 doi "https://doi.org/10.1182/blood-2018-05-852277" @default.
- W2890188806 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6302281" @default.
- W2890188806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30209118" @default.
- W2890188806 hasPublicationYear "2018" @default.
- W2890188806 type Work @default.
- W2890188806 sameAs 2890188806 @default.
- W2890188806 citedByCount "26" @default.
- W2890188806 countsByYear W28901888062018 @default.
- W2890188806 countsByYear W28901888062019 @default.
- W2890188806 countsByYear W28901888062020 @default.
- W2890188806 countsByYear W28901888062021 @default.
- W2890188806 countsByYear W28901888062022 @default.
- W2890188806 countsByYear W28901888062023 @default.
- W2890188806 crossrefType "journal-article" @default.